GRIFFIN MICHELLE RENEE 4
4 · Adaptive Biotechnologies Corp · Filed Mar 5, 2026
Insider Transaction Report
Form 4
GRIFFIN MICHELLE RENEE
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-03$3.99/sh+48,044$191,696→ 63,438 total - Sale
Common Stock
[F1][F2]2026-03-03$15.30/sh−48,044$735,073→ 15,394 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F3]2026-03-03−48,044→ 0 totalExercise: $3.99Exp: 2034-03-03→ Common Stock (48,044 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
- [F2]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $15.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The option is fully vested and exercisable.
Signature
Michelle Griffin by Kyle Piskel, Attorney-in-Fact|2026-03-05